Mediclin (MED.DE) Stock Price
Mediclin Price
Revenue has compounded at 3.9% per year over the past 19 years to 784.49 M EUR. Earnings per share have grown at 6.3% per year over the last 18 years. Mediclin's net margin stands at 3.2%, up from 0.2% several years earlier. Mediclin currently offers a dividend yield of about 0.80%. The payout ratio is around 7% of earnings. Analysts set a median price target of 5.87 EUR, implying 17.3% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Mediclin stock price
Mediclin business model & stock analysis
Frequently asked questions about Mediclin
The business model of Mediclin AG, a leading healthcare provider, revolves around offering a diverse range of medical services and high-quality patient care. With a focus on providing acute care, rehabilitation, and post-acute care, Mediclin AG operates a network of clinics and hospitals across Germany. Its services include specialized medical treatments, innovative therapies, and comprehensive aftercare programs. By constantly striving for medical excellence and employing experienced healthcare professionals, Mediclin AG aims to deliver optimal outcomes for patients. This company's commitment to delivering superior healthcare services has made it a trusted and reliable choice for individuals seeking top-notch medical care in Germany.
Mediclin AG is primarily active in the healthcare industry.
The main competitors of Mediclin AG in the market include big players like Fresenius SE & Co. KGaA, RHÖN-KLINIKUM AG, and Asklepios Kliniken GmbH & Co. KGaA.
Mediclin AG is a renowned healthcare company based in Germany. With a rich history spanning several decades, Mediclin AG has established itself as a leading provider of medical services and rehabilitation facilities. The company focuses on offering high-quality patient care through a network of clinics, acute care hospitals, and outpatient facilities across the country. Mediclin AG is committed to delivering comprehensive healthcare solutions, encompassing various specialties and treatment options. Their dedication to innovation, expertise, and a patient-centered approach has positioned Mediclin AG as a trusted name in the healthcare industry. Continually evolving and adapting to meet the changing needs of the society, Mediclin AG remains dedicated to improving the overall well-being of individuals by delivering exceptional medical care.
Mediclin AG has achieved several significant milestones in its journey. With a strong focus on providing excellent healthcare services, the company has expanded its network and gained recognition in the industry. Mediclin AG has successfully established state-of-the-art medical facilities, attracting renowned doctors and specialists. Through strategic partnerships and acquisitions, Mediclin AG has enhanced its service offerings and geographical presence. The company's commitment to patient care, innovative treatments, and continuous improvement has earned it a reputable position in the healthcare sector. These milestones have propelled Mediclin AG towards further growth and success in delivering high-quality healthcare services to patients.
Mediclin AG is primarily present in Germany.
Mediclin AG represents a set of core values and a corporate philosophy focused on providing high-quality healthcare services. With a strong emphasis on patient-centric care, Mediclin AG aims to prioritize the well-being and satisfaction of patients. The company strives to deliver excellent medical outcomes by continuously investing in cutting-edge technology and medical expertise. Medical professionalism, integrity, and ethical conduct are central to Mediclin AG's approach, ensuring that patients receive reliable and trustworthy healthcare services. By promoting collaboration among medical professionals and fostering a supportive environment, Mediclin AG aims to create a positive and healing experience for all patients.
Analysts currently set an average price target of 5.87 EUR for the Mediclin stock (median: 5.87 EUR), implying +15.0 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Mediclin stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Mediclin to generate revenue of 824.00 M EUR and earnings per share of 0.79 EUR.
The Mediclin share (MED.DE) is listed on 7 stock exchanges, including: London (0NDG.L), SIX (Zürich) (MEDCHF.SW), XETRA (MED.DE), Frankfurt (MED.F), München (MED.MU), Düsseldorf (MED.DU), Hamburg (MED.HM).
The Mediclin AG is a company in the healthcare sector that offers various services. The company's headquarters is located in Offenburg and it has clinics, rehabilitation facilities, and nursing homes throughout Germany. The company's divisions include acute hospitals, rehabilitation, post-acute medicine, nursing, and outpatient care. Acute hospitals treat patients with acute illnesses and injuries. The rehabilitation and post-acute medicine departments specialize in helping patients recover after accidents or surgeries. The nursing departments are responsible for caring for older or dependent people. The outpatient services offer various medical services that are provided outside of a hospital setting. Among the products offered by the company are check-up programs in which patients are examined for their health condition. In addition, the company also offers various weight reduction and personal development programs. Additionally, the company offers a variety of therapy services such as physiotherapy, occupational therapy, and speech therapy. The goal of Mediclin AG is to be a holistic healthcare provider that helps people stay healthy and fit on all levels. This means that the company not only offers medical services, but also is active on a psychological and social level. Another business field of the company is research and development. Mediclin AG is involved in various research projects aimed at improving medical care. The company works closely with universities and other research institutes to develop new and innovative methods and technologies. Mediclin AG is a listed company and is listed on the Frankfurt Stock Exchange. The company has a solid financial structure and is able to invest in growth and innovation to increase its competitiveness. Overall, Mediclin AG offers a variety of medical services and products to help people lead healthier lives on many levels. The company follows a comprehensive strategy that ranges from research and development to patient care and is continuously focused on innovation and renewal. Mediclin AG strives to be a reliable and trustworthy partner to its customers in their search for health and well-being.
The expected revenue of Mediclin is 824.00 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Mediclin is 37.60 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Mediclin is currently 6.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mediclin stock.
The price-to-sales ratio (P/S) of Mediclin is currently 0.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mediclin stock.
The Eulerpool Quality Score for Mediclin is 2/10.
The ISIN of Mediclin is DE0006595101. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Mediclin is 659510. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Mediclin is MED.DE. The ticker symbol is used to trade Mediclin shares on the stock exchange.
Mediclin stock
Mediclin Peer Group
Mediclin Ticker
Mediclin FIGI
All fundamentals and in-depth analysis of Mediclin
Our stock analysis for Mediclin stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mediclin. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.